A meta-analysis suggests adverse events are often falsely attributed to BP-lowering drugs, leaving patients undertreated.

Durability questions remain, but Myval appears comparable to contemporary devices on the market, says Patrick Serruys.

After the sponsor halted the trial, despite the DSMB’s advice to continue, investigators aimed to salvage the scientific value.

Women continue to be underdiagnosed and undertreated for cardiovascular disease around the world—to overcome this gap, a new joint statement from the European Society of Cardiology (ESC) and other ...

This month: questionable value of management consultants, BP across the lifespan, patient frailty perspectives in HF, and more.

The curves for TVF separated early and remained parallel in the complex cases, giving an advantage to the DCB group at 1 year ...

Top-line results from the phase III trial show average weight losses of 19% to 28.3% by 80 weeks depending on dose.

For stabilized patients undergoing complex PCI, left ventricular unloading with an Impella CP microaxial flow pump ...

Pieter Martens, MD, PhD (Hospital Oost-Limburg, Genk, Belgium), who made the “pro” case on behalf of IV iron, pointed out ...

Adverse pregnancy outcomes were linked to higher BP, BMI, and other cardiometabolic risk factors in kids 20 years later.

The Bioadaptor coronary implant (Elixir Medical) continues to outperform contemporary drug-eluting stent technology over ...

Baxdrostat (Baxfendy) has been approved by the US Food and Drug Administration for the treatment of patients with hypertension who have inadequately controlled blood pressure despite taking other ...